<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65470">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938638</url>
  </required_header>
  <id_info>
    <org_study_id>16519</org_study_id>
    <nct_id>NCT01938638</nct_id>
  </id_info>
  <brief_title>Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer</brief_title>
  <official_title>An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and the pharmacokinetics
      of BAY1143572 in subjects with advanced malignancies, which are either refractory to or
      ineligible for treatment with standard agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BAY1143572</measure>
    <time_frame>Up to 1 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during Cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum total bound drug concentration (Cmax) in plasma after single dose administration</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on day 1 and day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY1143572 [continuous]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1143572 [on/off]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule (Note: the dosing schedule may be changed to an alternative intermittent schedule based on e.g. initial human safety and tolerability, PK, or PD results).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1143572</intervention_name>
    <arm_group_label>BAY1143572 [continuous]</arm_group_label>
    <arm_group_label>BAY1143572 [on/off]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged &gt;/=21 years

          -  Subjects with advanced, histologically or cytologically confirmed advanced
             malignancies, refractory to any standard therapy, have no standard therapy available,
             or subjects must have actively refused any treatment which would be regarded
             standard, and / or if in the judgment of the investigator, experimental treatment is
             clinically and ethically acceptable.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy of at least 12 weeks

          -  Adequate bone marrow, liver, and renal functions as assessed by laboratory analysis
             to be conducted within 14 days prior to the first dose of study drug

          -  International normalized ratio (INR) and partial thromboplastin time (PTT) &lt;/=1.5
             times ULN (upper limit of normal)

        Exclusion Criteria:

          -  Known hypersensitivity to the study drug or excipients of the preparation or any
             agent given in association with this study

          -  History of cardiac disease including congestive heart failure &gt; New York Heart
             Association (NYHA) Class II, unstable angina (anginal symptoms at rest) or new-onset
             angina (within the last 6 months) or myocardial infarction within the past 6 months
             and cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers
             and digoxin; evidence for uncontrolled coronary artery disease (e.g. angina pectoris,
             myocardial infarction within 6 months prior to study entry, major regional wall
             motion abnormalities upon baseline echocardiography

          -  Uncontrolled hypertension defined as systolic blood pressure &gt;150 mmHg or diastolic
             blood pressure &gt;90 mmHg, despite optimal medical management

          -  Active clinically serious infections of &gt; Grade 2

          -  Uncontrolled seizure disorder requiring therapy (such as steroids or anti-epileptics
             with significant CYP interaction)

          -  Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of &gt;
             Grade 2 within 4 weeks prior to the first dose of study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
